KLDO (Kaleido Biosciences) OCF Margin %: -3,487.80% (As of Dec. 2021)


What is Kaleido Biosciences OCF Margin %?

Kaleido Biosciences KLDO OCF Margin % is -3,487.80% as of Dec. 2021.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kaleido Biosciences's Cash Flow from Operations for the three months ended in Dec. 2021 was $-17.16 Mil. Kaleido Biosciences's Revenue for the three months ended in Dec. 2021 was $0.49 Mil. Therefore, Kaleido Biosciences's OCF Margin % for the quarter that ended in Dec. 2021 was -3,487.80%.

As of today, Kaleido Biosciences's current OCF Yield % is -1,927,350.00%.

The historical rank and industry rank for Kaleido Biosciences's OCF Margin % or its related term are showing as below:

KLDO' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -6983.15

KLDO's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -66.52 vs KLDO: -6983.15

Kaleido Biosciences OCF Margin % Related Terms

Kaleido Biosciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences OCF Margin % Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -6,309.54 -6,983.15

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,648.97 -8,072.05 -9,518.01 -15,266.35 -3,487.80

KLDO vs NPTX, GSTC, BZYR: OCF Margin % Comparison

For the Biotechnology subindustry, Kaleido Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaleido Biosciences OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's OCF Margin % falls into.


Kaleido Biosciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kaleido Biosciences's OCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-77.094/1.104
=-6,983.15 %

Kaleido Biosciences's OCF Margin for the quarter that ended in Dec. 2021 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2021 )/Revenue (Q: Dec. 2021 )
=-17.16/0.492
=-3,487.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -3,487.80% mean?
Kaleido Biosciences (KLDO) has a OCF Margin % of -3,487.80% as of Dec. 2021. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' OCF Margin % too high?
Kaleido Biosciences' current OCF Margin % is -3,487.80%.
How does Kaleido Biosciences' OCF Margin % compare to NPTX and GSTC?
Kaleido Biosciences' OCF Margin % of -3,487.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current OCF Margin % is -3,487.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current OCF Margin % of -3,487.80%. The current OCF Margin % is -3,487.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current OCF Margin % is -3,487.80% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.